SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors

Kratochwil, Clemens; Stefanova, M.; Mavriopoulou, Eleni; Holland‐Letz, Tim; Dimitrakopoulou-Strauß, Antonia; Afshar‐Oromieh, Ali; Mier, Walter; Haberkorn, Uwe; Giesel, Frederik L.

doi:10.1007/s11307-014-0795-3

Cited by 192 publications

(131 citation statements)

References 16 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…The second point implies that the amount of tracer uptake is also of considerable importance, because higher radioiodine uptake predicts a better treatment response. In the case of neuroendocrine tumors, there is a positive correlation between the degree of somatostatin receptor expression and the treatment response as well as prognosis (15,16); however, in the current study, the SUV max of 68 Ga-PSMA-11 did not significantly influence the treatment response. One explanation for this difference between somatostatin receptor imaging and PSMA imaging may be the physiopathologic mechanism of tracer uptake.…”

Section: Discussioncontrasting

confidence: 84%

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with ¹⁷⁷Lu-PSMA-617

et al. 2016

View full text Add to dashboard Cite

Radioligand therapy (RLT) with 177 Lu-PSMA-617 (PSMA is prostatespecific membrane antigen) is a novel targeted therapy for metastatic prostate cancer. In this study, we evaluated the effect of different pretherapeutic parameters on the therapeutic response measured by prostate-specific antigen (PSA) 2 mo after RLT. Methods: RLT was performed in 40 hormone-refractory patients with distant metastases and progressive disease (mean age, 71.4 y). 68 Ga-PSMA-11 PET/CT was performed in all patients 1-2 wk before RLT. All patients were treated with a mean of 6 GBq. The SUV max of tumor lesions was determined using region-of-interest analysis. Complete blood counts, renal and liver function assessments, previous therapies, pain medication, and SUVs were included in the analysis. PSA was assessed 2 mo after RLT. Results: In the univariate analysis, younger age, higher levels of g-glutamyl transferase, lower pretherapeutic hemoglobin, a higher Gleason score, a higher number of platelets, higher C-reactive protein, regular need for pain medication, and higher lactate dehydrogenase had a negative impact on the therapeutic response; however, the multivariate analysis revealed that the most significant independent factors were the number of platelets and regular need for pain medication. The response was independent of the amount of PSMA uptake as well as previous therapies and other measured factors. Conclusion: A PSA decline of more than 50% was observed significantly more in patients without a regular need for analgesics.

show abstract

Section: Discussioncontrasting

confidence: 84%

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with ¹⁷⁷Lu-PSMA-617

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Kratochwil et al assessed the SSTR2 expression of the liver metastases in NET patients at baseline and after peptide receptor radiation therapy by measuring SUVmax, tumor to spleen ratio (T/S ratio), and tumor to liver ratio (T/L ratio) using Ga-68 DOTATOC [42]. Using the receiver operating characteristic curves, SUVmax was found a better metric than both T/L ratio and T/S ratios as a stratification criterion in this study.…”

Section: Splenic Uptake On Sstr Imaging Studiesmentioning

confidence: 59%

Significance of splenic uptake on somatostatin receptor imaging studies

Sarıkaya¹,

Sarıkaya²,

Alnafisi³

et al. 2018

Nucl. Med. Rev.

View full text Add to dashboard Cite

Spleen shows a high physiological uptake on radionuclide somatostatin receptor (SSTR) imaging studies. Autoradiography and immunohistochemistry studies showed that SSTRs are mainly located in the red pulp of the spleen. In this review article we will summarize the significance of splenic uptake in SSTR imaging studies and will also present high resolution splenic images of Ga-68 DOTANOC PET in which splenic distribution of the radiotracer appears to be correlating with the distribution of red pulp.

show abstract

“…The same concept can be applied to 68 Ga-SSA PET/CT imaging (e.g., on the volumetric image). Furthermore, uptake can be objectively quantified as SUV, which strongly correlates (linearly under a threshold of 25) with the inhibitor constant on dynamic PET and, hence, SSTR levels (19)(20)(21). Although criteria have been validated for 111 In-pentetreotide with the 4-point Krenning scale, there is no consensus on what should be considered sufficient uptake on 68 Ga-SSA PET/CT.…”

Section: Receptor Quantificationmentioning

confidence: 99%

Somatostatin Receptor 2–Targeting Compounds

Duijzentkunst

Bodei

2017

J Nucl Med

View full text Add to dashboard Cite

The molecular imaging and treatment of neuroendocrine tumors (NETs) with radiolabeled somatostatin analogs represent a milestone in the development of theranostic compounds. Whole-body scintigraphy with 111 In-pentetreotide has revolutionized the diagnosis and staging of NETs and the evaluation of treatment outcomes. At present, diagnostic accuracy with positron-emitting radionuclides is greater than 90%. Peptide receptor radionuclide therapy (PRRT) has become a well-accepted treatment for patients with welldifferentiated inoperable or metastatic NETs and disease progression after first-line treatment. Disease control rates (complete or partial remission or stable disease in patients with formerly progressive disease) of up to 95%, with a low incidence of long-term hematologic and renal toxicity, have been reported. In a recently published randomized trial, compared with intensified treatment of midgut NETs with longacting and repeatable octreotide, PRRT reduced the hazard of disease progression and death by 79%. Upcoming developments in PRRT include the use of somatostatin receptor antagonists and a-emitting radionuclides, which may further enhance treatment outcomes.

show abstract

SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors

Cited by 192 publications

References 16 publications

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with ¹⁷⁷Lu-PSMA-617

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with ¹⁷⁷Lu-PSMA-617

Significance of splenic uptake on somatostatin receptor imaging studies

Somatostatin Receptor 2–Targeting Compounds

Contact Info

Product

Resources

About

SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors

Cited by 192 publications

References 16 publications

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617

Significance of splenic uptake on somatostatin receptor imaging studies

Somatostatin Receptor 2–Targeting Compounds

Contact Info

Product

Resources

About

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with ¹⁷⁷Lu-PSMA-617

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with ¹⁷⁷Lu-PSMA-617